By the time an investor sends a term sheet, they've usually already run their own diligence on you. Not the formal kind with a data room and a checklist. The quiet kind: reading your LinkedIn history, searching your name alongside your last company, checking whether a clinician they trust has ever mentioned you.
Most founders don't think about that diligence until it's already happening. By then it's too late to shape it. The archive an associate finds is whatever you happened to publish, in whatever order, with whatever gaps sit between posts. You don't get a second draft of the last eighteen months.
Here's the thing founders miss: the proof stack that gets you through diligence isn't built during the raise. It's built in the months before anyone asks for it, and it's built out of content, not metrics you don't have yet.
That's a hard sell to a founder buried in product work. Content feels like the thing you'll get to after the round closes, once there's a marketing hire to own it. But the round is exactly when the archive gets read the hardest, and by then it's a record of what you did or didn't publish, not a task you can still complete on time.
Diligence starts weeks before the first call
An associate doesn't wait for the pitch to start researching. She's often read your last ten LinkedIn posts before the intro call is booked. If a partner is genuinely interested, she'll read the ten before that too.
What she's looking for isn't a result. Early-stage digital health rarely has one worth showing yet. She's looking for a pattern: does this founder think clearly, write specifically, and say the same thing in public that they'll say in the deck.
That last part matters more than founders expect. A pitch deck says "we're the trusted platform for chronic care management." A LinkedIn post from four months ago says "we're still working out whether async check-ins actually reduce no-shows, and here's what week six taught us." An associate who reads both doesn't see a contradiction. She sees a founder who's honest in public and confident in private, which is a much better signal than a founder who's polished everywhere and precise nowhere.
Proof, before you have a lead investor
Founders default to thinking proof means traction: revenue, retention, a signed LOI from a health system. That's one kind, and it's rarely available this early.
There's a second kind available from day one: proof of judgment. It shows up in how you describe the problem, how you talk about what you got wrong, and whether your public claims are specific enough that a competitor couldn't have written the same sentence.
Judgment proof doesn't replace traction proof. It buys you time to build traction proof without going quiet in the meantime, and it's the thing an associate can actually verify before the round even opens, because it's sitting in public where she can read it herself.
The four things an associate actually checks
Archive depth and consistency. Follower count and viral hits don't matter here. Rhythm does. A founder who's published every two weeks for eight months, even to a small audience, reads as someone who executes. A founder with three posts in a year, all written the week before a raise, reads as someone reacting to pressure rather than building a practice.
One claim she can check. Vague statements ("we're transforming chronic care") don't help her. A specific, falsifiable claim does: "physio no-shows in our pilot dropped from 22% to 14% over ten weeks, in a group of 12 providers." She can call the pilot lead and verify that in one phone call. That's what makes it proof instead of marketing.
A name attached to validation. A quote from a clinical advisor who's actually used the product, reacting honestly to something specific carries weight. A testimonial that says "great platform" carries none. Specificity is what separates a real endorsement from a favor.
Narrative consistency across channels. Does the deck's framing of the problem match what you've written about the problem for the last year? A market insight that suddenly appears on slide four, with no trace of it anywhere in your public writing, reads as a warning sign to an associate who's paying attention. Story lines that appear fully formed the week of a raise tend to get noticed.
Building each piece without inventing anything
Start with the archive. Pick a cadence you can actually sustain, every two weeks is enough, and write about what you're testing, not what you've already proven. A short post on a workflow assumption that didn't hold up does more for your credibility than a polished claim with nothing behind it.
For the checkable claim, write down your baseline the day a pilot starts. Most founders skip this and end up guessing at "before" numbers eight months later, which is the fastest way to turn a real result into something that sounds made up. If you don't have a real number yet, say so plainly and mark exactly where it'll go: [PLACEHOLDER — replace with real result].
For third-party validation, ask an advisor for a reaction to something specific you wrote, not a general endorsement of the company. Specific reactions read as real because they usually are. General ones read as favors because they usually are too.
For narrative consistency, go back and read your own archive against your current deck before anyone else does. If they've drifted apart, that's worth fixing before an associate finds the gap for you.
The clinical diligence track runs at the same time
Investors aren't the only ones checking. A clinical advisory board, a pilot site's medical director, or a health system's innovation lead is running a parallel version of the same process, and she's often harder to convince than the associate is.
She's not reading for execution signal. She's reading for whether you understand her world well enough that the product is likely to survive contact with an actual clinic. A post that names the exact moment documentation eats into a physio's day does more for her trust than a case study with a big number and no context, because the specificity proves you've spent real time in her world.
This is also where founders trip themselves up by writing one version of everything for two different audiences. That splits your attention and dilutes both versions. A single story, written precisely enough that a clinician recognizes something true in it, tends to earn an investor's trust too. The fact that satisfies her is usually the same fact that convinces him you understand the market.
What kills credibility here
Overclaiming is the obvious one. A logo wall of pilots who haven't renewed, or "trusted by leading providers" with no name attached, reads as a warning sign to both a clinician and an investor who've seen the same empty phrase from a dozen other vendors.
The less obvious one is over-hedging. Founders who get nervous about sounding premature start writing "we believe," "early indications suggest," and "it's possible that" in every sentence. Read three paragraphs of that and the founder sounds unsure of their own product, which is a worse signal than being early.
You can say plainly that you're six weeks into a pilot with no outcome data yet, and still write with total conviction about why the problem matters and why your approach is right. Being honest about stage and being confident about your point of view aren't the same thing. Keep them separate.
Where to start this week
Pull up your last ten posts or articles. Count how many contain a specific, checkable fact versus a general claim about your mission. If it's fewer than half, that's the first thing to fix.
Then check your deck against that same archive. If the market insight in slide four has never once shown up in anything you've published, write about it now, before anyone asks where it came from.
Finally, pick one pilot detail you can write about honestly today: what you're testing, why that group, what you'd change if you're wrong. That single post, dated and specific, is worth more in a diligence conversation eight months from now than a case study you're still hoping to have by then.
None of this requires a result you don't have. It requires being willing to say, in public, exactly what you know and exactly what you don't, months before anyone runs a formal check on whether that's true.
Why this matters more in digital health than almost anywhere else
A B2B SaaS founder selling into marketing teams can get away with a thinner archive. A digital health founder can't, because the two audiences reading it, clinicians and investors, are both trained to spot overclaiming, and both talk to each other more than founders expect. A skeptical clinical advisor's private comment to a friend at a fund travels faster than any press release you'll write.
An empty or overclaiming archive costs more than one missed investor. It builds a reputation that follows you into rooms you're not in.
The upside runs the same direction. A founder with eight months of specific, honest writing behind them walks into a partner meeting with something a slide can't replicate: a public record that says this person thinks clearly under uncertainty. That record took time to build, which is exactly why it's hard for a competitor to fake it in the six weeks before their own raise.